Tests a personalized hydroxyurea dose for children with sickle cell disease
Tests hydroxyurea dosed to each child's absorption in sickle cell anemia.
Plain-language title generated from the registry record
Registry title: Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
Key facts
- Where
- Cincinnati, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Trial code
- NCT07177300
- Record updated
- 16 September 2025
- Original description
The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA.Read full original descriptionShow less
Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA.
In this research study, the investigators hope to learn more about how to improve the dosing and monitoring of hydroxyurea and learn more about the long-term effects of hydroxyurea over time. Hydroxyurea is usually dosed based only on your weight. Our study will use a new way to select a starting dose that is based on how each patient absorbs hydroxyurea.
Inclusion: Diagnosis of sickle cell anemia (HbSS) or sickle-β0-thalassemia (HbSβ0); Age 6 months at the time of enrollment; Clinical decision by patient, family, and healthcare provider to initiate hydroxyurea therapy.
Exclusion: Current treatment with regularly scheduled blood transfusions; Sickle-hemoglobin C disease (HbSC), sickle-β+-thalassemia (HbSβ+).